Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers
Por:
Stjepanovic, N, Lubinski, J, Moller, P, Armel, SR, Foulkes, WD, Tung, N, Neuhausen, SL, Kotsopoulos, J, Sun, P, Sun, S, Eisen, A, Narod, SA, Cajal, T.R., Bordeleau, Louise J.
Publicada:
1 jun 2021
Ahead of Print:
1 ene 2021
Resumen:
Purpose It is not known whether the risk of breast cancer among BRCA1 and BRCA2 mutation carriers after age 60 is high enough to justify intensive screening or prophylactic surgery. Thus, we conducted a prospective analysis of breast cancer risk in BRCA1 and BRCA2 mutation carriers from age 60 until age 80. Methods Subjects had no history of cancer and both breasts intact at age 60 (n = 699). Women were followed until a breast cancer diagnosis, prophylactic bilateral mastectomy or death. We calculated the annual cancer rate and cumulative incidence of breast cancer (invasive and in situ) from age 60 to age 80. We assessed the associations between hormone replacement therapy, family history of breast cancer and bilateral oophorectomy and breast cancer risk. Results Over a mean follow-up of 7.9 years, 61 invasive and 20 in situ breast cancers were diagnosed in the cohort. The mean annual rate of invasive breast cancer was 1.8% for BRCA1 mutation carriers and 1.7% for BRCA2 mutation carriers. The cumulative risk of invasive breast cancer from age 60 to 80 was 20.1% for women with a BRCA1 mutation and was 17.3% for women with a BRCA2 mutation. Hormone replacement therapy, family history and oophorectomy were not associated with breast cancer risk. Conclusions Findings from this large prospective study indicate that the risk of developing breast cancer remains high after age 60 in both BRCA1 and BRCA2 mutation carriers. These findings warrant further evaluation of the role of breast cancer screening in older mutation carriers.
Filiaciones:
Stjepanovic, N:
Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada
Lubinski, J:
Pomeranian Med Univ, Int Hereditary Canc Ctr, Dept Genet & Pathol, Szczecin, Poland
Moller, P:
Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Tumor Biol, Oslo, Norway
Armel, SR:
Univ Hlth Network, Toronto, ON, Canada
Foulkes, WD:
McGill Univ, Dept Oncol & Human Genet, Program Canc Genet, Montreal, PQ, Canada
Tung, N:
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
Neuhausen, SL:
City Of Hope, Dept Populat Sci, Div Biomarkers Early Detect & Prevent, Duarte, CA USA
Kotsopoulos, J:
Womens Coll Hosp, Womens Coll Res Inst, 76 Grenville St,6th Floor, Toronto, ON M5S 1B2, Canada
Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada
Sun, P:
Womens Coll Hosp, Womens Coll Res Inst, 76 Grenville St,6th Floor, Toronto, ON M5S 1B2, Canada
Sun, S:
BC Canc Agcy, Vancouver, BC, Canada
Eisen, A:
Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada
Narod, SA:
Womens Coll Hosp, Womens Coll Res Inst, 76 Grenville St,6th Floor, Toronto, ON M5S 1B2, Canada
Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada
Cajal, T.R.:
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Bordeleau, Louise J.:
McMaster University, Hamilton, Canada
|